---
document_datetime: 2025-12-02 05:00:12
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/myocet-liposomal.html
document_name: myocet-liposomal.html
version: success
processing_time: 0.1097129
conversion_datetime: 2025-12-25 05:41:10.779147
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Myocet liposomal (previously Myocet)

[RSS](/en/individual-human-medicine.xml/66800)

##### Authorised

This medicine is authorised for use in the European Union

doxorubicin Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Myocet liposomal is a cancer medicine for use with cyclophosphamide (another cancer medicine) to treat women with metastatic breast cancer. 'Metastatic' means that the cancer has spread to other parts of the body.

Myocet liposomal contains the active substance doxorubicin.

Expand section

Collapse section

## How is Myocet liposomal used?

Myocet liposomal can only be obtained with a prescription and it should be given under the supervision of a doctor experienced in the use of cytotoxic chemotherapy (cell-killing cancer treatment). It should be given in a specialised unit for giving chemotherapy.

Myocet liposomal is given every 3 weeks by infusion (drip) into a vein over an hour. The dose is calculated on the basis of the woman's weight and height. The doctor may interrupt treatment or reduce the dose if certain side effects develop.

For more information about using Myocet liposomal, see the package leaflet or contact your doctor or pharmacist.

## How does Myocet liposomal work?

The active substance in Myocet liposomal, doxorubicin, is a cytotoxic (cell-killing) medicine that belongs to the group 'anthracyclines'. It works by interfering with the DNA in cells, preventing the cells from making copies of DNA and from making proteins. This means that cancer cells cannot divide and eventually die. Because Myocet liposomal builds up in tumours, its effect is concentrated there.

Doxorubicin has been available since the 1960s. In Myocet liposomal, doxorubicin is enclosed in tiny fat particles called 'liposomes'. This helps to protect the heart and the gut from doxorubicin's harmful effects and so reduces side effects.

## What benefits of Myocet liposomal have been shown in studies?

Three main studies involving a total of 681 women with metastatic breast cancer found treatment with Myocet liposomal for 6 weeks at least as effective as standard (non-liposomal) doxorubicin or another medicine used for the condition.

In the first study, the disease improved in 43% of women receiving either Myocet liposomal or standard doxorubicin, both combined with cyclophosphamide. In the second study, 26% of women receiving either Myocet liposomal alone or standard doxorubicin alone improved with treatment. In the third study, the disease improved in 46% of women receiving Myocet liposomal with cyclophosphamide compared with 39% of women receiving epirubicin (a medicine that works in the same way as doxorubicin) with cyclophosphamide.

Heart problems occurred less often in patients receiving Myocet liposomal than in those receiving standard doxorubicin.

## What are the risks associated with Myocet liposomal?

The most common side effects with Myocet liposomal (which may affect more than 1 in 10 people) are neutropenic fever (fever associated with low levels of neutrophils, a type of white blood cell), infection, neutropenia (low levels of neutrophils), thrombocytopenia (low blood platelet counts), anaemia (low red blood cell counts), leucopenia (low white blood cell counts), loss of appetite, nausea (feeling sick), vomiting, stomatitis (inflammation of the lining of the mouth), mucositis (inflammation of the moist body surfaces), diarrhoea, hair loss, weakness, fever, pain and rigors (shaking chills).

For the full list of side effects and restrictions of Myocet liposomal, see the package leaflet.

## Why is Myocet liposomal authorised in the EU?

Myocet liposomal has a lower risk of heart problems than conventional doxorubicin, while both medicines are similarly effective. The European Medicines Agency therefore decided that Myocet liposomal's benefits are greater than its risks and it can be authorised for use in the EU.

## What measures are being taken to ensure the safe and effective use of Myocet liposomal?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Myocet liposomal have been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Myocet liposomal are continuously monitored. Side effects reported with Myocet liposomal are carefully evaluated and any necessary action taken to protect patients.

## Other information about Myocet liposomal

Myocet liposomal received a marketing authorisation valid throughout the EU on 13 July 2000.

Myocet liposomal (previously Myocet) : EPAR - Medicine overview

Reference Number: EMA/631375/2019

English (EN) (176.92 KB - PDF)

**First published:** 07/03/2008

**Last updated:** 04/02/2020

[View](/en/documents/overview/myocet-liposomal-previously-myocet-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-876)

български (BG) (220.73 KB - PDF)

**First published:**

07/03/2008

**Last updated:**

04/02/2020

[View](/bg/documents/overview/myocet-liposomal-previously-myocet-epar-medicine-overview_bg.pdf)

español (ES) (176.96 KB - PDF)

**First published:**

07/03/2008

**Last updated:**

04/02/2020

[View](/es/documents/overview/myocet-liposomal-previously-myocet-epar-medicine-overview_es.pdf)

čeština (CS) (197.52 KB - PDF)

**First published:**

07/03/2008

**Last updated:**

04/02/2020

[View](/cs/documents/overview/myocet-liposomal-previously-myocet-epar-medicine-overview_cs.pdf)

dansk (DA) (173.58 KB - PDF)

**First published:**

07/03/2008

**Last updated:**

04/02/2020

[View](/da/documents/overview/myocet-liposomal-previously-myocet-epar-medicine-overview_da.pdf)

Deutsch (DE) (178.58 KB - PDF)

**First published:**

07/03/2008

**Last updated:**

04/02/2020

[View](/de/documents/overview/myocet-liposomal-previously-myocet-epar-medicine-overview_de.pdf)

eesti keel (ET) (162.24 KB - PDF)

**First published:**

07/03/2008

**Last updated:**

04/02/2020

[View](/et/documents/overview/myocet-liposomal-previously-myocet-epar-medicine-overview_et.pdf)

ελληνικά (EL) (221 KB - PDF)

**First published:**

07/03/2008

**Last updated:**

04/02/2020

[View](/el/documents/overview/myocet-liposomal-previously-myocet-epar-medicine-overview_el.pdf)

français (FR) (177.8 KB - PDF)

**First published:**

07/03/2008

**Last updated:**

04/02/2020

[View](/fr/documents/overview/myocet-liposomal-previously-myocet-epar-medicine-overview_fr.pdf)

hrvatski (HR) (196.3 KB - PDF)

**First published:**

07/03/2008

**Last updated:**

04/02/2020

[View](/hr/documents/overview/myocet-liposomal-previously-myocet-epar-medicine-overview_hr.pdf)

italiano (IT) (175.61 KB - PDF)

**First published:**

07/03/2008

**Last updated:**

04/02/2020

[View](/it/documents/overview/myocet-liposomal-previously-myocet-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (213.58 KB - PDF)

**First published:**

07/03/2008

**Last updated:**

04/02/2020

[View](/lv/documents/overview/myocet-liposomal-previously-myocet-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (197.21 KB - PDF)

**First published:**

07/03/2008

**Last updated:**

04/02/2020

[View](/lt/documents/overview/myocet-liposomal-previously-myocet-epar-medicine-overview_lt.pdf)

magyar (HU) (198.06 KB - PDF)

**First published:**

07/03/2008

**Last updated:**

04/02/2020

[View](/hu/documents/overview/myocet-liposomal-previously-myocet-epar-medicine-overview_hu.pdf)

Malti (MT) (218.96 KB - PDF)

**First published:**

07/03/2008

**Last updated:**

04/02/2020

[View](/mt/documents/overview/myocet-liposomal-previously-myocet-epar-medicine-overview_mt.pdf)

Nederlands (NL) (175.82 KB - PDF)

**First published:**

07/03/2008

**Last updated:**

04/02/2020

[View](/nl/documents/overview/myocet-liposomal-previously-myocet-epar-medicine-overview_nl.pdf)

polski (PL) (200.98 KB - PDF)

**First published:**

07/03/2008

**Last updated:**

04/02/2020

[View](/pl/documents/overview/myocet-liposomal-previously-myocet-epar-medicine-overview_pl.pdf)

português (PT) (177.84 KB - PDF)

**First published:**

07/03/2008

**Last updated:**

04/02/2020

[View](/pt/documents/overview/myocet-liposomal-previously-myocet-epar-medicine-overview_pt.pdf)

română (RO) (195.48 KB - PDF)

**First published:**

07/03/2008

**Last updated:**

04/02/2020

[View](/ro/documents/overview/myocet-liposomal-previously-myocet-epar-medicine-overview_ro.pdf)

slovenčina (SK) (196.6 KB - PDF)

**First published:**

07/03/2008

**Last updated:**

04/02/2020

[View](/sk/documents/overview/myocet-liposomal-previously-myocet-epar-medicine-overview_sk.pdf)

slovenščina (SL) (195.85 KB - PDF)

**First published:**

07/03/2008

**Last updated:**

04/02/2020

[View](/sl/documents/overview/myocet-liposomal-previously-myocet-epar-medicine-overview_sl.pdf)

Suomi (FI) (173.83 KB - PDF)

**First published:**

07/03/2008

**Last updated:**

04/02/2020

[View](/fi/documents/overview/myocet-liposomal-previously-myocet-epar-medicine-overview_fi.pdf)

svenska (SV) (173.08 KB - PDF)

**First published:**

07/03/2008

**Last updated:**

04/02/2020

[View](/sv/documents/overview/myocet-liposomal-previously-myocet-epar-medicine-overview_sv.pdf)

## Product information

Myocet liposomal : EPAR - Product Information

English (EN) (379.08 KB - PDF)

**First published:** 12/11/2009

**Last updated:** 06/06/2024

[View](/en/documents/product-information/myocet-liposomal-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-189)

български (BG) (431.99 KB - PDF)

**First published:**

12/11/2009

**Last updated:**

06/06/2024

[View](/bg/documents/product-information/myocet-liposomal-epar-product-information_bg.pdf)

español (ES) (394.48 KB - PDF)

**First published:**

12/11/2009

**Last updated:**

06/06/2024

[View](/es/documents/product-information/myocet-liposomal-epar-product-information_es.pdf)

čeština (CS) (410.06 KB - PDF)

**First published:**

12/11/2009

**Last updated:**

06/06/2024

[View](/cs/documents/product-information/myocet-liposomal-epar-product-information_cs.pdf)

dansk (DA) (369.7 KB - PDF)

**First published:**

12/11/2009

**Last updated:**

06/06/2024

[View](/da/documents/product-information/myocet-liposomal-epar-product-information_da.pdf)

Deutsch (DE) (388.59 KB - PDF)

**First published:**

12/11/2009

**Last updated:**

06/06/2024

[View](/de/documents/product-information/myocet-liposomal-epar-product-information_de.pdf)

eesti keel (ET) (362.73 KB - PDF)

**First published:**

12/11/2009

**Last updated:**

06/06/2024

[View](/et/documents/product-information/myocet-liposomal-epar-product-information_et.pdf)

ελληνικά (EL) (447.94 KB - PDF)

**First published:**

12/11/2009

**Last updated:**

06/06/2024

[View](/el/documents/product-information/myocet-liposomal-epar-product-information_el.pdf)

français (FR) (407.37 KB - PDF)

**First published:**

12/11/2009

**Last updated:**

06/06/2024

[View](/fr/documents/product-information/myocet-liposomal-epar-product-information_fr.pdf)

hrvatski (HR) (414.02 KB - PDF)

**First published:**

12/11/2009

**Last updated:**

06/06/2024

[View](/hr/documents/product-information/myocet-liposomal-epar-product-information_hr.pdf)

íslenska (IS) (362.82 KB - PDF)

**First published:**

12/11/2009

**Last updated:**

06/06/2024

[View](/is/documents/product-information/myocet-liposomal-epar-product-information_is.pdf)

italiano (IT) (377.35 KB - PDF)

**First published:**

12/11/2009

**Last updated:**

06/06/2024

[View](/it/documents/product-information/myocet-liposomal-epar-product-information_it.pdf)

latviešu valoda (LV) (417.51 KB - PDF)

**First published:**

12/11/2009

**Last updated:**

06/06/2024

[View](/lv/documents/product-information/myocet-liposomal-epar-product-information_lv.pdf)

lietuvių kalba (LT) (426.13 KB - PDF)

**First published:**

12/11/2009

**Last updated:**

06/06/2024

[View](/lt/documents/product-information/myocet-liposomal-epar-product-information_lt.pdf)

magyar (HU) (458.94 KB - PDF)

**First published:**

12/11/2009

**Last updated:**

06/06/2024

[View](/hu/documents/product-information/myocet-liposomal-epar-product-information_hu.pdf)

Malti (MT) (460.91 KB - PDF)

**First published:**

12/11/2009

**Last updated:**

06/06/2024

[View](/mt/documents/product-information/myocet-liposomal-epar-product-information_mt.pdf)

Nederlands (NL) (353.7 KB - PDF)

**First published:**

12/11/2009

**Last updated:**

06/06/2024

[View](/nl/documents/product-information/myocet-liposomal-epar-product-information_nl.pdf)

norsk (NO) (375.29 KB - PDF)

**First published:**

12/11/2009

**Last updated:**

06/06/2024

[View](/no/documents/product-information/myocet-liposomal-epar-product-information_no.pdf)

polski (PL) (444.02 KB - PDF)

**First published:**

12/11/2009

**Last updated:**

06/06/2024

[View](/pl/documents/product-information/myocet-liposomal-epar-product-information_pl.pdf)

português (PT) (371.76 KB - PDF)

**First published:**

12/11/2009

**Last updated:**

06/06/2024

[View](/pt/documents/product-information/myocet-liposomal-epar-product-information_pt.pdf)

română (RO) (479.09 KB - PDF)

**First published:**

12/11/2009

**Last updated:**

06/06/2024

[View](/ro/documents/product-information/myocet-liposomal-epar-product-information_ro.pdf)

slovenčina (SK) (457.95 KB - PDF)

**First published:**

12/11/2009

**Last updated:**

06/06/2024

[View](/sk/documents/product-information/myocet-liposomal-epar-product-information_sk.pdf)

slovenščina (SL) (413.54 KB - PDF)

**First published:**

12/11/2009

**Last updated:**

06/06/2024

[View](/sl/documents/product-information/myocet-liposomal-epar-product-information_sl.pdf)

Suomi (FI) (384.61 KB - PDF)

**First published:**

12/11/2009

**Last updated:**

06/06/2024

[View](/fi/documents/product-information/myocet-liposomal-epar-product-information_fi.pdf)

svenska (SV) (349.56 KB - PDF)

**First published:**

12/11/2009

**Last updated:**

06/06/2024

[View](/sv/documents/product-information/myocet-liposomal-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** T/0073 29/05/2024

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Myocet liposomal (previously Myocet) : EPAR - All Authorised presentations

English (EN) (14.72 KB - PDF)

**First published:** 16/08/2008

**Last updated:** 07/05/2021

[View](/en/documents/all-authorised-presentations/myocet-liposomal-previously-myocet-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-227)

български (BG) (40.42 KB - PDF)

**First published:**

16/08/2008

**Last updated:**

07/05/2021

[View](/bg/documents/all-authorised-presentations/myocet-liposomal-previously-myocet-epar-all-authorised-presentations_bg.pdf)

español (ES) (13.64 KB - PDF)

**First published:**

16/08/2008

**Last updated:**

07/05/2021

[View](/es/documents/all-authorised-presentations/myocet-liposomal-previously-myocet-epar-all-authorised-presentations_es.pdf)

čeština (CS) (35.71 KB - PDF)

**First published:**

16/08/2008

**Last updated:**

07/05/2021

[View](/cs/documents/all-authorised-presentations/myocet-liposomal-previously-myocet-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (14.77 KB - PDF)

**First published:**

16/08/2008

**Last updated:**

07/05/2021

[View](/da/documents/all-authorised-presentations/myocet-liposomal-previously-myocet-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (14 KB - PDF)

**First published:**

16/08/2008

**Last updated:**

07/05/2021

[View](/de/documents/all-authorised-presentations/myocet-liposomal-previously-myocet-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (14.87 KB - PDF)

**First published:**

16/08/2008

**Last updated:**

07/05/2021

[View](/et/documents/all-authorised-presentations/myocet-liposomal-previously-myocet-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (39.32 KB - PDF)

**First published:**

16/08/2008

**Last updated:**

07/05/2021

[View](/el/documents/all-authorised-presentations/myocet-liposomal-previously-myocet-epar-all-authorised-presentations_el.pdf)

français (FR) (15.05 KB - PDF)

**First published:**

16/08/2008

**Last updated:**

07/05/2021

[View](/fr/documents/all-authorised-presentations/myocet-liposomal-previously-myocet-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (32.53 KB - PDF)

**First published:**

16/08/2008

**Last updated:**

07/05/2021

[View](/hr/documents/all-authorised-presentations/myocet-liposomal-previously-myocet-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (14.77 KB - PDF)

**First published:**

16/08/2008

**Last updated:**

07/05/2021

[View](/is/documents/all-authorised-presentations/myocet-liposomal-previously-myocet-epar-all-authorised-presentations_is.pdf)

italiano (IT) (14.88 KB - PDF)

**First published:**

16/08/2008

**Last updated:**

07/05/2021

[View](/it/documents/all-authorised-presentations/myocet-liposomal-previously-myocet-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (36.77 KB - PDF)

**First published:**

16/08/2008

**Last updated:**

07/05/2021

[View](/lv/documents/all-authorised-presentations/myocet-liposomal-previously-myocet-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (35.99 KB - PDF)

**First published:**

16/08/2008

**Last updated:**

07/05/2021

[View](/lt/documents/all-authorised-presentations/myocet-liposomal-previously-myocet-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (22.61 KB - PDF)

**First published:**

16/08/2008

**Last updated:**

07/05/2021

[View](/hu/documents/all-authorised-presentations/myocet-liposomal-previously-myocet-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (35 KB - PDF)

**First published:**

16/08/2008

**Last updated:**

07/05/2021

[View](/mt/documents/all-authorised-presentations/myocet-liposomal-previously-myocet-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (13.95 KB - PDF)

**First published:**

16/08/2008

**Last updated:**

07/05/2021

[View](/nl/documents/all-authorised-presentations/myocet-liposomal-previously-myocet-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (13.59 KB - PDF)

**First published:**

16/08/2008

**Last updated:**

07/05/2021

[View](/no/documents/all-authorised-presentations/myocet-liposomal-previously-myocet-epar-all-authorised-presentations_no.pdf)

polski (PL) (35.61 KB - PDF)

**First published:**

16/08/2008

**Last updated:**

07/05/2021

[View](/pl/documents/all-authorised-presentations/myocet-liposomal-previously-myocet-epar-all-authorised-presentations_pl.pdf)

português (PT) (14.75 KB - PDF)

**First published:**

16/08/2008

**Last updated:**

07/05/2021

[View](/pt/documents/all-authorised-presentations/myocet-liposomal-previously-myocet-epar-all-authorised-presentations_pt.pdf)

română (RO) (35.34 KB - PDF)

**First published:**

16/08/2008

**Last updated:**

07/05/2021

[View](/ro/documents/all-authorised-presentations/myocet-liposomal-previously-myocet-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (35.3 KB - PDF)

**First published:**

16/08/2008

**Last updated:**

07/05/2021

[View](/sk/documents/all-authorised-presentations/myocet-liposomal-previously-myocet-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (22.25 KB - PDF)

**First published:**

16/08/2008

**Last updated:**

07/05/2021

[View](/sl/documents/all-authorised-presentations/myocet-liposomal-previously-myocet-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (14.82 KB - PDF)

**First published:**

16/08/2008

**Last updated:**

07/05/2021

[View](/fi/documents/all-authorised-presentations/myocet-liposomal-previously-myocet-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (13.68 KB - PDF)

**First published:**

16/08/2008

**Last updated:**

07/05/2021

[View](/sv/documents/all-authorised-presentations/myocet-liposomal-previously-myocet-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Myocet liposomal (previously Myocet) Active substance doxorubicin hydrochloride International non-proprietary name (INN) or common name doxorubicin Therapeutic area (MeSH) Breast Neoplasms Anatomical therapeutic chemical (ATC) code L01DB01

### Pharmacotherapeutic group

Antineoplastic agents

### Therapeutic indication

Myocet liposomal, in combination with cyclophosphamide, is indicated for the first-line treatment of metastatic breast cancer in adult women.

## Authorisation details

EMA product number EMEA/H/C/000297 Marketing authorisation holder

CHEPLAPHARM Arzneimittel GmbH

Ziegelhof 24

Opinion adopted 12/04/2000 Marketing authorisation issued 13/07/2000 Revision 25

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Myocet liposomal (previously Myocet) : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (224.34 KB - PDF)

**First published:** 12/11/2009

**Last updated:** 06/06/2024

[View](/en/documents/procedural-steps-after/myocet-liposomal-previously-myocet-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Myocet-C-H-297-PSU-0019 : EPAR - Scientific conclusions and grounds recommending the variation to the terms of the marketing authorisations

Adopted

Reference Number: EMA/CHMP/605854/2013

English (EN) (63.8 KB - PDF)

**First published:** 06/11/2013

**Last updated:** 06/11/2013

[View](/en/documents/scientific-conclusion/myocet-c-h-297-psu-0019-epar-scientific-conclusions-and-grounds-recommending-variation-terms-marketing-authorisations_en.pdf)

Myocet : EPAR - Steps taken after authorisation when a cutoff date has been used

English (EN) (84.03 KB - PDF)

**First published:** 16/08/2006

**Last updated:** 16/08/2006

[View](/en/documents/steps-after-cutoff/myocet-epar-steps-taken-after-authorisation-when-cutoff-date-has-been-used_en.pdf)

## Initial marketing authorisation documents

Myocet : EPAR - Procedural steps taken before authorisation

English (EN) (85.46 KB - PDF)

**First published:** 16/08/2008

[View](/en/documents/procedural-steps/myocet-epar-procedural-steps-taken-authorisation_en.pdf)

Myocet : EPAR - Scientific Discussion

English (EN) (299.21 KB - PDF)

**First published:** 16/08/2006

**Last updated:** 16/08/2006

[View](/en/documents/scientific-discussion/myocet-epar-scientific-discussion_en.pdf)

#### Topics

- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 06/06/2024

## Share this page

[Back to top](#main-content)